Page 1,051«..1020..1,0501,0511,0521,053..1,0601,070..»

Gene Therapies for Regenerative Surgery Are Getting Closer, Says Review in Plastic and Reconstructive Surgery

ARLINGTON HEIGHTS, IL--(Marketwired - May 29, 2013) - Experimental genetic techniques may one day provide plastic and reconstructive surgeons with an invaluable tool -- the ability to promote growth of the patient's own tissues for reconstructive surgery. A review of recent progress toward developing effective gene therapies for use in "regenerative surgery" appears in the June issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons (ASPS).

Over the past ten years, researchers have developed several promising gene therapy techniques to grow skin, bone and other tissues for reconstructive surgery. But they still face many challenges in developing gene-based approaches that can make the leap from the research lab to the operating room, according to the review by Dr. Giorgio Giatsidis and colleagues of Padua University Hospital, Italy.

Gene Therapy Approaches Studied for 'Almost Every Tissue'Dr. Giatsidis and coauthors reviewed the state of the art in research on gene therapy techniques for treatment of local disorders and injuries -- the first such review in more than a decade. They found studies using gene therapy to promote the growth of "almost every different tissue" for use in regenerative surgery. "Gene therapy may represent a leading strategy to develop more efficient regenerative surgical treatments for numerous clinical needs," they write.

Gene therapy has the potential to provide reconstructive surgeons with a new approach to solving one of their most difficult problems: the lack of adequate tissues to correct deformities of a specific area or structure. For example, in patients with relatively small burns, plastic and reconstructive surgeons have designed a wide range of skin flaps for use in transferring healthy tissue to the burned area.

But for patients with burns involving larger areas, the lack of suitable tissues for coverage may severely limit the reconstructive options. Using gene techniques to promote growth of specific types of tissues would be a major step forward in the ability to perform truly regenerative surgery.

But Translation from Lab to OR Poses Many Challenges Several research groups are pursuing gene therapy approaches to regenerate skin, such as using genes to control expression of growth factors involved in skin healing. One small study reported promising results with tissue-engineered products to promote healing of diabetic skin ulcers.

Researchers are also targeting growth factors involved in new bone formation, with promising results in techniques using transplantation of genetically modified donor bone. One study reported clinical benefits using gene therapy to regenerate joint cartilage in patients with rheumatoid arthritis. Techniques to promote healing of tendons, regeneration of injured nerves, and growth of skin flaps for reconstructive surgery are all being explored.

But despite progress in all of these areas, translating experimental gene therapy methods into regenerative surgery techniques for use in the operating room will remain a difficult challenge. Even after the technical problems are addressed, more work will be needed to develop regenerative surgery techniques that are productive and cost-effective.

"After two decades, regenerative surgery is an adolescent looking forward to growing up," Dr. Giatsidis and coauthors write. "Despite extensive preclinical approaches, translation of gene therapy strategies into clinical trials is still a difficult and expensive process."

So far, the studies of diabetic ulcers and rheumatoid arthritis mentioned above are the only methods to show evidence of clinical effectiveness in human patients. "Even so," the authors add, "cutting-edge gene therapy-based strategies in reconstructive procedures [are close] to setting valuable milestones for development of efficient treatments in a growing number of local diseases and injuries."

The rest is here:
Gene Therapies for Regenerative Surgery Are Getting Closer, Says Review in Plastic and Reconstructive Surgery

Recommendation and review posted by Bethany Smith

Gene therapy boost in flu battle

Scientists may have discovered a new weapon in the war against influenza, according to a study.

Researchers in the US used a gene therapy technique which worked well against the H5N1 and H1N1 flu virus. Gene therapy is a new technique in which doctors can tackle a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.

Investigators at the Perelman School of Medicine, University of Pennsylvania, used a liquid to place a gene replicating an antibody known to be effective against flu into the noses of mice and ferrets, and found it gave them protection against lethal strains of the virus.

In the study, published in the journal Science Translational Medicine, the strains were isolated from samples associated with an infamous flu pandemic in 1918 and another in 2009.

One of the scientists, James Wilson, said: "The experiments described in our paper provide critical proof-of-concept in animals about a technology platform that can be deployed in the setting of virtually any pandemic or biological attack for which a neutralising antibody exists or can be easily isolated.

"Further development of this approach for pandemic flu has taken on more urgency in light of the spreading infection in China of the lethal bird strain of H7N9 virus in humans."

The technique establishes broad-based efficacy against a wide range of flu strains.

The treatment was tested in mice that were exposed to lethal quantities of three strains of H5N1 and two strains of H1N1, all of which have been associated with historic human pandemics (including the infamous H1N1 1918).

The flu virus rapidly replicated in untreated animals all of which needed to be put down. However, pre-treatment with the liquid containing the gene virtually shut down virus replication and provided complete protection against all strains of flu in the treated animals.

One of the scientists, Maria Limberis, said: "The novelty of this approach is that we're ... delivering the prophylactic vaccine to the nose in a non-invasive manner, not a shot like conventional vaccines that passively transfer antibodies to the general circulation."

Read more from the original source:
Gene therapy boost in flu battle

Recommendation and review posted by Bethany Smith

Gene Therapy May Protect Against Flu Pandemics

Study found coaxing cells in the nose to make super antibodies protected mice and ferrets from pandemic strains

WebMD News from HealthDay

By Brenda Goodman

HealthDay Reporter

WEDNESDAY, May 29 (HealthDay News) -- Gene therapy that turns cells in the nose into factories that crank out super antibodies against the flu protected mice and ferrets against lethal doses of several pandemic strains of the virus.

If the approach works in humans, it could offer several important advantages over flu vaccines, said study author Dr. James Wilson, a professor of pathology and laboratory medicine at the University of Pennsylvania, in Philadelphia.

Because the therapy can be made ahead of time and fights many different strains, it might give doctors a faster way to thwart flu pandemics.

Currently, doctors race to identify dangerous new types of flu. They then have to develop a vaccine that targets the new strain. The vaccine is then grown in chicken eggs and tested for safety. It takes between three and six months to manufacture large quantities of vaccines against the flu.

"By the time we realize it's a potential pandemic, it's too late," Wilson said. "The timeliness of deploying the seasonal flu vaccine approach for pandemics is not the best way to go."

Vaccines, which prime the body to remember to attack incoming pathogens, also don't do the best job of protecting people who have diminished immune function, such as seniors and those with chronic health problems.

The rest is here:
Gene Therapy May Protect Against Flu Pandemics

Recommendation and review posted by Bethany Smith

New Gene Therapy Shows Broad Protection in Animal Models to Pandemic Flu Strains, including the Deadly 1918 Spanish …

PHILADELPHIA Researchers at the Perelman School of Medicine, University of Pennsylvania have developed a new gene therapy to thwart a potential influenza pandemic. Specifically, investigators in the Gene Therapy Program, Department of Pathology and Laboratory Medicine, directed by James M. Wilson, MD, PhD, demonstrated that a single dose of an adeno-associated virus (AAV) expressing a broadly neutralizing flu antibody into the nasal passages of mice and ferrets gives them complete protection and substantial reductions in flu replication when exposed to lethal strains of H5N1 and H1N1 flu virus. These strains were isolated from samples associated from historic human pandemics one from the infamous 1918 flu pandemic and another from 2009.

Wilson, Anna Tretiakova, PhD, Senior Research Scientist, Maria P. Limberis, PhD, Research Assistant Professor, all from the Penn Gene Therapy Program, and colleagues published their findings online this week in Science Translational Medicine ahead of print. In addition to the Penn scientists, the international effort included colleagues from the Public Health Agency of Canada, Winnipeg; the University of Manitoba, Winnipeg; and the University of Pittsburgh. Tretiakova is also the director of translational research, and Limberis is the director of animal models core, both with the Gene Therapy Program.

The experiments described in our paper provide critical proof-of-concept in animals about a technology platform that can be deployed in the setting of virtually any pandemic or biological attack for which a neutralizing antibody exists or can be easily isolated, says Wilson. Further development of this approach for pandemic flu has taken on more urgency in light of the spreading infection in China of the lethal bird strain of H7N9 virus in humans.

Influenza infections are the seventh leading cause of death in the United States and result in almost 500,000 deaths worldwide per year, according to the Centers for Disease Control. The emergence of a new influenza pandemic remains a threat that could result in a much loss of life and worldwide economic disruption.

There is also interest by the military in developing an off-the-shelf prophylactic vaccine should soldiers be exposed to weaponized strains of infectious agents in biologic warfare.

Human antibodies with broad neutralizing activity against various influenza strains exist but their direct use as a prophylactic treatment is impractical. Now, yearly flu vaccines are made by growing the flu virus in eggs. The viral envelope proteins on the exterior, namely hemagglutinin, are cleaved off and used as the vaccine, but vary from year to year, depending on what flu strains are prevalent. However, high mutation rates in the proteins result in the emergence of new viral types each year, which elude neutralization by preexisting antibodies in the body (specifically specific receptor binding sites on the virus that are the targets of neutralizing antibodies).

This approach has led to annual vaccinations against seasonal strains of flu viruses that are predicted to emerge during the upcoming season. Strains that arise outside of the human population, for example in domestic livestock, are distinct from those that normally circulate in humans, and can lead to deadly pandemics.

These strains are also not effectively controlled by vaccines developed to human strains, as with the 2009 H1N1 pandemic. The vaccine development time for that strain, and in general, was not fast enough to support vaccination in response to an emerging pandemic.

Knowing this, the Penn team proposed a novel approach that does not require the elicitation of an immune response, which does not provide sufficient breadth to be useful against any strain of flu other than the one for which it was designed, as with conventional approaches.

The Penn approach is to clone into a vector a gene that encodes an antibody that is effective against many strains of flu and to engineer cells that line the nasal passages to express this broadly neutralizing antibody, effectively establishing broad-based efficacy against a wide range of flu strains.

More:
New Gene Therapy Shows Broad Protection in Animal Models to Pandemic Flu Strains, including the Deadly 1918 Spanish ...

Recommendation and review posted by Bethany Smith

Gene therapy gives mice broad protection to pandemic flu strains, including 1918 flu

May 29, 2013 Researchers at the Perelman School of Medicine, University of Pennsylvania have developed a new gene therapy to thwart a potential influenza pandemic. Specifically, investigators in the Gene Therapy Program, Department of Pathology and Laboratory Medicine, directed by James M. Wilson, MD, PhD, demonstrated that a single dose of an adeno-associated virus (AAV) expressing a broadly neutralizing flu antibody into the nasal passages of mice and ferrets gives them complete protection and substantial reductions in flu replication when exposed to lethal strains of H5N1 and H1N1 flu virus. These strains were isolated from samples associated from historic human pandemics -- one from the infamous 1918 flu pandemic and another from 2009.

Wilson, Anna Tretiakova, PhD, Senior Research Scientist, Maria P. Limberis, PhD, Research Assistant Professor, all from the Penn Gene Therapy Program, and colleagues published their findings online this week in Science Translational Medicine ahead of print. In addition to the Penn scientists, the international effort included colleagues from the Public Health Agency of Canada, Winnipeg; the University of Manitoba, Winnipeg; and the University of Pittsburgh. Tretiakova is also the director of translational research, and Limberis is the director of animal models core, both with the Gene Therapy Program.

"The experiments described in our paper provide critical proof-of-concept in animals about a technology platform that can be deployed in the setting of virtually any pandemic or biological attack for which a neutralizing antibody exists or can be easily isolated," says Wilson. "Further development of this approach for pandemic flu has taken on more urgency in light of the spreading infection in China of the lethal bird strain of H7N9 virus in humans."

At the Ready Influenza infections are the seventh leading cause of death in the United States and result in almost 500,000 deaths worldwide per year, according to the Centers for Disease Control. The emergence of a new influenza pandemic remains a threat that could result in a much loss of life and worldwide economic disruption.

There is also interest by the military in developing an off-the-shelf prophylactic vaccine should soldiers be exposed to weaponized strains of infectious agents in biologic warfare.

Human antibodies with broad neutralizing activity against various influenza strains exist but their direct use as a prophylactic treatment is impractical. Now, yearly flu vaccines are made by growing the flu virus in eggs. The viral envelope proteins on the exterior, namely hemagglutinin, are cleaved off and used as the vaccine, but vary from year to year, depending on what flu strains are prevalent. However, high mutation rates in the proteins result in the emergence of new viral types each year, which elude neutralization by preexisting antibodies in the body (specifically specific receptor binding sites on the virus that are the targets of neutralizing antibodies).

This approach has led to annual vaccinations against seasonal strains of flu viruses that are predicted to emerge during the upcoming season. Strains that arise outside of the human population, for example in domestic livestock, are distinct from those that normally circulate in humans, and can lead to deadly pandemics.

These strains are also not effectively controlled by vaccines developed to human strains, as with the 2009 H1N1 pandemic. The vaccine development time for that strain, and in general, was not fast enough to support vaccination in response to an emerging pandemic.

Knowing this, the Penn team proposed a novel approach that does not require the elicitation of an immune response, which does not provide sufficient breadth to be useful against any strain of flu other than the one for which it was designed, as with conventional approaches.

The Penn approach is to clone into a vector a gene that encodes an antibody that is effective against many strains of flu and to engineer cells that line the nasal passages to express this broadly neutralizing antibody, effectively establishing broad-based efficacy against a wide range of flu strains.

Go here to see the original:
Gene therapy gives mice broad protection to pandemic flu strains, including 1918 flu

Recommendation and review posted by Bethany Smith

Stem Cell Therapy Treatment for Myotonic Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. – Video


Stem Cell Therapy Treatment for Myotonic Muscular Dystrophy by Dr Alok Sharma, Mumbai, India.
Improvement seen in just 3 months after Stem Cell Therapy Treatment for Myotonic Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy...

By: NeuroGen Brain And Spine Institute

Visit link:
Stem Cell Therapy Treatment for Myotonic Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. - Video

Recommendation and review posted by simmons

Stem Cell Therapy Treatment for Becker Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. – Video


Stem Cell Therapy Treatment for Becker Muscular Dystrophy by Dr Alok Sharma, Mumbai, India.
Improvement seen after Stem Cell Therapy Treatment for Becker Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. Stem Cell Therapy done at Dr Alok Sharma N...

By: NeuroGen Brain And Spine Institute

More here:
Stem Cell Therapy Treatment for Becker Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. - Video

Recommendation and review posted by simmons

Dina Firchmin – Cell Therapy Foundation ‘Rejuvenate Breakfast’ – Video


Dina Firchmin - Cell Therapy Foundation #39;Rejuvenate Breakfast #39;
Dina Firchmin speaks at the Cell Therapy Foundation #39;s #39;Rejuvenate Breakfast #39;

By: Ryan Alan Petti

Here is the original post:
Dina Firchmin - Cell Therapy Foundation 'Rejuvenate Breakfast' - Video

Recommendation and review posted by Bethany Smith

Traci Runge – Cell Therapy Foundation’s ‘Rejuvenate Breakfast’ – Video


Traci Runge - Cell Therapy Foundation #39;s #39;Rejuvenate Breakfast #39;
Traci Runge speaks at the Cell Therapy Foundation #39;s #39;Rejuvenate Breakfast #39;

By: Ryan Alan Petti

Here is the original post:
Traci Runge - Cell Therapy Foundation's 'Rejuvenate Breakfast' - Video

Recommendation and review posted by Bethany Smith

Dr. Bruce Van Natta – Cell Therapy Foundation’s ‘Rejuvenate Breakfast’ – Video


Dr. Bruce Van Natta - Cell Therapy Foundation #39;s #39;Rejuvenate Breakfast #39;
Dr. Bruce Van Natta speaks at the Cell Therapy Foundation #39;s #39;Rejuvenate Breakfast #39;

By: Ryan Alan Petti

Read more here:
Dr. Bruce Van Natta - Cell Therapy Foundation's 'Rejuvenate Breakfast' - Video

Recommendation and review posted by Bethany Smith

Dr Keith March – Cell Therapy Foundation’s ‘Rejuvenate Breakfast’ – Video


Dr Keith March - Cell Therapy Foundation #39;s #39;Rejuvenate Breakfast #39;
Dr Keith March speaks at the Cell Therapy Foundation #39;s #39;Rejuvenate Breakfast #39;

By: Ryan Alan Petti

See more here:
Dr Keith March - Cell Therapy Foundation's 'Rejuvenate Breakfast' - Video

Recommendation and review posted by Bethany Smith

GM Salmon, Genetic Engineering of Farm Animals to Arrive in Summer 2013 Despite Public Opposition – Video


GM Salmon, Genetic Engineering of Farm Animals to Arrive in Summer 2013 Despite Public Opposition
By summer of 2013, US governing bodies, or, the alphabet soup of corruption (USDA, FDA, etc.) are expected to grant permission for scientists to roll out gen...

By: Love one and be loved one

See more here:
GM Salmon, Genetic Engineering of Farm Animals to Arrive in Summer 2013 Despite Public Opposition - Video

Recommendation and review posted by Bethany Smith

New 1-step process for designer bacteria

Public release date: 26-May-2013 [ | E-mail | Share ]

Contact: Dr. Keith Shearwin keith.shearwin@adelaide.edu.au 61-883-135-361 University of Adelaide

A simpler and faster way of producing designer bacteria used in biotechnology processes has been developed by University of Adelaide researchers.

The researchers have developed a new one-step bacterial genetic engineering process called 'clonetegration', published in the journal ACS Synthetic Biology.

Led by Dr Keith Shearwin, in the University's School of Molecular and Biomedical Sciences, the research facilitates faster development of designer bacteria used in therapeutic drug development, such as insulin, and other biotechnology products.

Designer bacteria are produced by integrating extra pieces of genetic material into the DNA of bacteria, in this case E. coli, so that the bacteria will make a desired product.

"E. coli strains are commonly used workhorses for biotechnology and metabolic engineering," Dr Shearwin says.

"For example, new genes or even the genetic material for whole metabolic pathways are inserted into the bacteria's chromosome so that they produce compounds or proteins not normally produced. Insulin is an example of a therapeutic product produced in this way."

"The existing process for integrating new genes is inefficient, taking several days. Our new process can be completed overnight."

As well as speeding up the process, 'clonetegration' enables multiple rounds of genetic engineering on the same bacteria, and simultaneous integration of multiple genes at different specific locations.

Read this article:
New 1-step process for designer bacteria

Recommendation and review posted by Bethany Smith

U of A medical researchers ID genetic marker for sporadic breast cancer

Public release date: 28-May-2013 [ | E-mail | Share ]

Contact: Raquel Maurier rmaurier@ualberta.ca 780-492-5986 University of Alberta Faculty of Medicine & Dentistry

Medical researchers at the University of Alberta have pinpointed a genetic marker for sporadic breast cancer one of a handful identified to date in Caucasians.

Researchers have identified many genetic markers for familial breast cancers, but not for sporadic breast cancer which accounts for 80 per cent of all cases. Sambasivarao Damaraju, a professor with the Faculty of Medicine & Dentistry and a researcher at the Cross Cancer Institute, worked with his team to scan the DNA of about 7,200 Alberta women, including those who have had sporadic breast cancer and those who have not had cancer. Their genomes were scanned from DNA isolated from blood.

The results? Women who had sporadic breast cancer frequently had a genetic marker on chromosome 4 a marker that has never been associated with familial breast cancer cases.

"The frequency of this marker occurring was statistically significant," says Damaraju, who works in the Department of Laboratory Medicine & Pathology. "Genetic factors that predispose women to breast cancer is a subject of intense investigation in the research world. While 60 to 70 genetic risk factors have been identified for familial breast cancer, we don't know much about the genetic risk factors for sporadic breast cancer. So this finding is exciting, and shows us more research is needed in this area."

The team's findings were recently published in the peer-reviewed journal, PLoS One. Damaraju noted the team, which included co-author John Mackey and PhD student Yadav Sapkota, was multi-disciplinary, including basic scientists, medical oncologists, biostatisticians and epidemiologists. He also acknowledged the initial contributions to this work from previous trainees, Malinee Sridharan and Badan S. Sehrawat. Overall, he collaborated with colleagues from the U of A's School of Public Health, the Department of Oncology, and the Department of Agricultural, Food and Nutritional Sciences, as well as colleagues from the Cross Cancer Institute and Alberta Health Services.

Damaraju and his team are continuing their work in this very young field (the first genetic marker for breast cancer predisposition was reported in 2007). He says more research is needed to identify genetic markers for sporadic breast cancer, but that large scale screening to identify those at risk is still years away.

Lifestyle factors account for two-thirds of the risk associated with breast cancer, while the remaining one-third of the risk is attributed to genetics, Damaraju noted.

The research was funded by the Alberta Cancer Foundation and the Canadian Breast Cancer Foundation Prairies/NWT region.

Read the rest here:
U of A medical researchers ID genetic marker for sporadic breast cancer

Recommendation and review posted by Bethany Smith

Family studies suggest rare genetic mutations team up to cause schizophrenia

Public release date: 28-May-2013 [ | E-mail | Share ]

Contact: Shawna Williams shawna@jhmi.edu 410-955-8236 Johns Hopkins Medicine

Using a novel method of analyzing genetic variations in families, researchers at Johns Hopkins have found that individually harmless genetic variations affecting related biochemical processes may team up to increase the risk of schizophrenia. They say their findings, reported May 28 in Translational Psychiatry, bring some clarity to the murky relationship between genetics and schizophrenia, and may lead to a genetic test that can predict which medications will be effective for individual patients.

"It's long been clear that schizophrenia runs in families, but schizophrenia as a simple inherited disease didn't make sense from an evolutionary point of view because people with the disease tend to have fewer children and the disease-causing genetic variants shouldn't survive," says Dimitri Avramopoulos, M.D., Ph.D., an associate professor of psychiatry in the McKusick-Nathans Institute of Genetic Medicine. Moreover, he says, studies searching for schizophrenia-linked gene variants have found only weak connections to a few genes nothing that would explain the persistent prevalence of the disease, which affects about 1 percent of the population.

Most geneticists believe that the culprit in so-called complex genetic diseases such as schizophrenia is not just one genetic variant, but more than one acting in concert. It's also likely that individual cases of the disease are caused by different combinations of variants, Avramopoulos says. He and fellow researchers took this hypothesis a step further, theorizing that while our bodies can usually compensate for one faulty gene that affects a particular system, more than one hit to the same system is likely to tip people toward disease.

The research team devised a technique for analyzing gene-sequencing data that explores whether variants cluster in a subset of cases in a non-random way. After finding support for their hypothesis in previously obtained data on 123 families with at least two schizophrenia-affected members, they decided to sequence genes connected through a biochemical chain reaction that has been linked to the disease in 48 inpatients. Known as the neuregulin signaling pathway, that chain reaction relays signals within the nervous system.

As they had predicted, the researchers found that some of the families had multiple neuregulin signaling-related variants while others had none, a distribution that was highly unlikely to result from chance. Moreover, the schizophrenia patients with neuregulin signaling variants experienced more hallucinations but less impairment than the other schizophrenia patients in the study.

"These results support the idea that there's no single genetic recipe for schizophrenia, but that a buildup of mutations in a pathway related to the disease like neuregulin signaling can be the culprit," Avramopoulos says. "The results are also evidence for the current theory that schizophrenia isn't a single disease at all, but a suite of related disorders." Those patients in the study who did not have neuregulin signaling-related variants likely carried variants in a different pathway instead, he notes.

While the results of the study were surprisingly clear-cut given the small number of families in the study, Avramopoulos cautions that larger studies are needed to confirm the results before drawing any firm conclusions. He also plans to study the exact roles of the schizophrenia-linked variants the team identified. Finally, the encouraging results mean it would be worthwhile to apply the new analytic method to other common diseases, such as diabetes and heart disease, which also appear to have complex genetic roots.

###

Here is the original post:
Family studies suggest rare genetic mutations team up to cause schizophrenia

Recommendation and review posted by Bethany Smith

MATURE GENETICS – Video


MATURE GENETICS
ART MUSIC VIDEO.

By: art zaninon

Read more:
MATURE GENETICS - Video

Recommendation and review posted by Bethany Smith

RACING PIGEON EYE SELECTION 1 – Video


RACING PIGEON EYE SELECTION 1
WHAT TO LOOK FOR IN THE EYE..RACING PIGEON SELECTION AND PAIRING MADE EASY REMEMBER 1ST GENETICS ,2ND GENETICS,3RD GENETICS AND THEN COME THE REST.

By: wynand wolmarans

See the original post here:
RACING PIGEON EYE SELECTION 1 - Video

Recommendation and review posted by Bethany Smith

RACING PIGEON EYE SIGN-THE GREEN EYE – Video


RACING PIGEON EYE SIGN-THE GREEN EYE
HOW TO LOOK FOR THE GREEN EVERYBODY IS TALKING ABOUT. WHAT TO LOOK FOR IN THE EYE..RACING PIGEON SELECTION AND PAIRING MADE EASY REMEMBER 1ST GENETICS ,2ND G...

By: wynand wolmarans

Read the rest here:
RACING PIGEON EYE SIGN-THE GREEN EYE - Video

Recommendation and review posted by Bethany Smith

VetRegen stem cell therapy. – Video


VetRegen stem cell therapy.
Please watch this Video though in Polish most is visual. I took out the longer news cast that was Filmed Live in Warsaw My wife Joanna was asked too be on a ...

By: stephen sanford

Follow this link:
VetRegen stem cell therapy. - Video

Recommendation and review posted by Bethany Smith

Stem Cell Therapy A New Investigational Approach To Arthritis Relief – Video


Stem Cell Therapy A New Investigational Approach To Arthritis Relief
http://www.innovationsstemcellcenter.com 214.699.6948.

By: InnovationsStemCell

View original post here:
Stem Cell Therapy A New Investigational Approach To Arthritis Relief - Video

Recommendation and review posted by Bethany Smith

Brodie Before


Brodie Before After Stemlogix Stem Cell Therapy
Brodie a 3 year old rottweiler had a complete cranial cruciate ligament tear of his left rear leg. Dr. Stephanie Meyer at the Creatures Great Small Vet Hos...

By: Stemlogix LLC #39;s Channel

Visit link:
Brodie Before

Recommendation and review posted by Bethany Smith

UK & World News: Stem cell therapy 'shows results'

May 27 2013

Five stroke victims have shown small signs of recovery following pioneering stem cell therapy.

Prof Keith Muir, of Glasgow University, said the results were "not what we would have expected" from the group of patients who had previously shown no indications of their conditions improving.

The trial involved injecting stem cells directly into the damaged parts of the patients' brains, with the hope that they would turn into healthy tissue or "kick-start" the body's own repair processes.

Frank Marsh, 80, one of the nine patients taking part in the trial at Glasgow's Southern General Hospital, told the BBC he had seen improvements in the use of his left hand.

"I can grip certain things that I never gripped before, like the hand rail at the baths, with my left hand as well as my right," he said."It still feels fairly weak and it's still a wee bit difficult to co-ordinate, but it's much better than it was." He added: "I'd like to get back to playing my piano."

His wife Claire said: "He had reached a plateau and wasn't really improving (after his stroke). But following the operation he is able to do things he couldn't do before, such as make coffee, dressing and holding on to things."

The study involved patients who suffered strokes some time ago and had shown no signs of making any further spontaneous improvement.

Prof Muir said the results were "at the present time not what we would have expected in this group but far from being able to say whether it's something specifically related to the cells".

He told BBC Radio 4's Today programme: "We know that some of the cells will survive and potentially turn into relevant tissue. We also suspect that a large part of what we do is kick-starting repair processes that are already present in the body. So there's probably a mixture of things going on. Quite what it is that's happening in the patients, we won't know for some time to come."

Original post:
UK & World News: Stem cell therapy 'shows results'

Recommendation and review posted by Bethany Smith

Stroke victims show signs of recovery following pioneering stem cell therapy

Five stroke victims have shown small signs of recovery following pioneering stem cell therapy.

Prof Keith Muir, of Glasgow University, said the results were "not what we would have expected" from the group of patients who had previously shown no indications of their conditions improving.

The trial involved injecting stem cells directly into the damaged parts of the patients' brains, with the hope that they would turn into healthy tissue or "kick-start" the body's own repair processes.

Frank Marsh, 80, one of the nine patients taking part in the trial at Glasgow's Southern General Hospital, told the BBC he had seen improvements in the use of his left hand.

"I can grip certain things that I never gripped before, like the hand rail at the baths, with my left hand as well as my right," he said."It still feels fairly weak and it's still a wee bit difficult to co-ordinate but it's much better than it was."He added: "I'd like to get back to playing my piano."

His wife Claire said: "He had reached a plateau and wasn't really improving (after his stroke). But following the operation he is able to do things he couldn't do before, such as make coffee, dressing, and holding on to things."

The study involved patients who suffered strokes some time ago and had shown no signs of making any further spontaneous improvement.

Prof Muir said the results were "at the present time not what we would have expected in this group but far from being able to say whether it's something specifically related to the cells".

He told BBC Radio 4's Today programme: "We know that some of the cells will survive and potentially turn into relevant tissue. We also suspect that a large part of what we do is kick-starting repair processes that are already present in the body.

"So there's probably a mixture of things going on. Quite what it is that's happening in the patients, we won't know for some time to come."

Continued here:
Stroke victims show signs of recovery following pioneering stem cell therapy

Recommendation and review posted by Bethany Smith

Stem cell therapy 'shows results'

Five stroke victims have shown small signs of recovery following pioneering stem cell therapy.

Prof Keith Muir, of Glasgow University, said the results were "not what we would have expected" from the group of patients who had previously shown no indications of their conditions improving.

The trial involved injecting stem cells directly into the damaged parts of the patients' brains, with the hope that they would turn into healthy tissue or "kick-start" the body's own repair processes.

Frank Marsh, 80, one of the nine patients taking part in the trial at Glasgow's Southern General Hospital, told the BBC he had seen improvements in the use of his left hand.

"I can grip certain things that I never gripped before, like the hand rail at the baths, with my left hand as well as my right," he said."It still feels fairly weak and it's still a wee bit difficult to co-ordinate, but it's much better than it was." He added: "I'd like to get back to playing my piano."

His wife Claire said: "He had reached a plateau and wasn't really improving (after his stroke). But following the operation he is able to do things he couldn't do before, such as make coffee, dressing and holding on to things."

The study involved patients who suffered strokes some time ago and had shown no signs of making any further spontaneous improvement.

Prof Muir said the results were "at the present time not what we would have expected in this group but far from being able to say whether it's something specifically related to the cells".

He told BBC Radio 4's Today programme: "We know that some of the cells will survive and potentially turn into relevant tissue. We also suspect that a large part of what we do is kick-starting repair processes that are already present in the body. So there's probably a mixture of things going on. Quite what it is that's happening in the patients, we won't know for some time to come."

The stem cells were created 10 years ago from one sample of nerve tissue taken from a foetus.

Read the original post:
Stem cell therapy 'shows results'

Recommendation and review posted by Bethany Smith

New gene discovery

May 26, 2013

A new gene associated with a form of congenital heart disease in new born babies known as 'a hole in the heart' has been discovered by researchers funded by us.

Scientists from across the world, led by BHF Professor of Cardiology Bernard Keavney, have analysed the genes of over 2,000 people with congenital heart disease to find specific genes linked to the condition.

Congenital heart disease affects about 1 in every 145 births. The researchers found a particular gene closely associated with one of the most common forms an atrial septal defect where there is a 'hole' between the atria, the two chambers at the top of the heart.

Dr Shannon Amoils, our Senior Research Advisor, said: Weve made great strides in treating congenital heart disease; most babies born with a heart defect have a much brighter future now than they would have had in the 1960s when the BHF was founded. But we still need to fund much more research like this, to better understand the fundamental causes of congenital heart defects.

These important results show how large collaborative studies are incredibly useful for uncovering the influence of our genes on congenital heart disease. As researchers continue to identify other associated genes, we will be able to better predict the chances of children being born with heart problems, and will also learn more about the underlying processes that can go wrong in the developing heart.

Breakthroughs like this are made possible thanks to our supporters.Donate today tohelp us continue the fight for every heartbeat.

The discovery was published in the journal Nature Genetics.

See original here:
New gene discovery

Recommendation and review posted by Bethany Smith


Archives